Syndax Pharmaceuticals Appoints Aaron Ondrey as CFO Following Keith Goldan's Retirement Announcement
Syndax Pharmaceuticals (SNDX) has announced a leadership transition in its finance department. Aaron Ondrey has been named the new Chief Financial Officer, with his appointment set to take effect on November 9, 2026. The outgoing CFO, Keith Goldan, will retire from the role but will remain with the company through the end of 2026. This extended transition period is intended to ensure continuity and support during the leadership handover.